Advaxis, Inc., ADXS announced that the first patient has been
dosed in a Phase 1/2 “window of opportunity” study being conducted by
the Icahn School of Medicine at Mount Sinai. Patients diagnosed with
HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy
during the “window” of time between initial diagnosis and minimally
invasive transoral robotic surgery (TORS) to remove their tumors.
HPV-associated head and neck cancer is the most rapidly growing form of
head and neck cancer, and is caused by the same virus that causes
cervical cancer.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in